OncoMatch/Clinical Trials/NCT07462377
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Is NCT07462377 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies EPI-326 for epidermal growth factor.
Treatment: EPI-326 — A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR any documented mutation, insertion, or deletion
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Kidney function
Liver function
Participant has adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- START Los Angeles · Los Angeles, California
- Astera Cancer Care · East Brunswick, New Jersey
- Sarah Cannon and HCA Research Institute · Nashville, Tennessee
- MD Anderson Cancer Center · Houston, Texas
- South Texas Accelerated Research Therapeutics (START) · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify